Cover Image
市場調查報告書

全球皮下注射治療市場與開發平台分析

Subcutaneous Drug Delivery Market & Pipeline Insight

出版商 PNS Pharma 商品編碼 323522
出版日期 內容資訊 英文 1800 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球皮下注射治療市場與開發平台分析 Subcutaneous Drug Delivery Market & Pipeline Insight
出版日期: 2015年01月29日 內容資訊: 英文 1800 Pages
簡介

創新的皮下注射治療劑及給藥設備,由於其眾多優點使全世界的需求擴大。透過皮下的藥物給藥的效力高,緩釋性,均一的吸收性帶給患者高治療效果,為了將副作用最小化,更多醫生也開皮下注射治療劑的處方。新的製劑也成為擴大市場普及的巨大的要素。還有皮下注射治療設備技術上也有很大的進步,今後可能會擴大佔有率。

本報告提供全球皮下注射治療劑及給藥設備市場趨勢的相關調查、皮下注射治療的機制、皮下注射治療市場概要、市場影響因素分析、給藥設備種類與概要、皮下注射治療劑的開發趨勢、已上市皮下注射治療劑概要、競爭環境、主要經營者簡介等彙整資料。

第1章 皮下注射治療:簡介

第2章 皮下注射治療的機制

第3章 皮下注射治療市場概要

  • 目前市場方案
  • 皮下注射治療劑的開發平台概要

第4章 皮下注射治療市場力學

  • 好意性的市場參數
  • 在臨床方面、商業方面的課題

第5章 皮下注射治療設備

  • 注射器
  • 皮下移植
  • 筆型注射器
  • 自動注射器
  • 幫浦型藥物遞輸系統

第6章 皮下注射治療市場未來展望

第7章 皮下注射治療劑的臨床實驗平台:各企業、適應症、階段

  • 未確認
  • 研究
  • 前臨床
  • 臨床
  • 第一階段
  • 第I/II相
  • 第二階段
  • 第II/III相
  • 第三階段
  • 前登記
  • 登記

第8章 已上市皮下注射治療劑:臨床性分析

第9章 臨床試驗中止、延期的皮下注射治療劑

  • 沒有發展報告
  • 中止
  • 前登記申請中止
  • 市場撤退
  • 延期

第10章 競爭環境

  • Boehringer Ingelheim
  • Eli Lily
  • Galaxo
  • HMD pharmaceuticals
  • Merck
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Sanofi
  • Teva Pharmaceutical
  • Zogenix

圖表

目錄

Subcutaneous sites along with intramuscular and intravenous sites are part of parenteral route of drug entry. Maximum pharmacological benefits of a drug could be achieved by deciding effective route of administration depending upon pharmacodynamic properties of the drug to be used. Subcutaneous route is commonly used for the administration of therapeutics into the body for better drug delivery of lipophilic, proteinecious, small molecule drugs. It is characterized by less vasculature, fat rich and less metabolic activity prevents the degradation of drugs resulting in long last effect and higher therapeutic effects.

Subcutaneous sites are versatile routes of administration that can be used for long-term therapeutic benefits. Implants are also placed in this site due to less nerve ending so that pain or discomfort is not produced when such devices are placed at the site. Owing to enormous fat reserves, they are found to have good absorbability for lipid soluble drugs which allows the researchers to design drugs according to the nature of subcutaneous site. Some drugs can't be used via other routes due to difference in their biochemical nature could be administrated subcutaneously. This site is metabolically less active due to which administrated drugs have lesser chances of degradation, enzyme activity and metabolic breakdown as a result of which many drugs could be administrated subcutaneously.

Proteins are important component of several drugs which can't be administrated through other routes like oral, intravenous or intramuscular. Protein based drugs are sensitive towards pH, extreme acidity, alkalinity and limited bioavailability causing limited number of sites for administration. For instance, insulin hormone for the treatment of Diabetes Miletus is a small protein administrated through subcutaneous route. Orally it can't be given due to low pH of stomach which will destroy insulin; intramuscularly it will be absorbed to quickly, while intravenous administration may have potentially high life threatening effects. Also, every year large number of protein based drugs are introduced in market for the treatment of various ailments. Subcutaneous sites are found throughout the body consisting of loose interstitial tissues that may be found in upper arm, anterior thigh surface and lower abdominal portion. These places have been found to be safe and effective for the subcutaneous drug administration.

Numerous benefits provided by innovative subcutaneous drugs and delivery devices have caused increase in their demand across the globe. Higher potency, sustained release and uniform absorption drugs from subcutaneous site has allowed patients to get more therapeutic benefits. More physicians prescribe subcutaneous drugs due to minimized side effects and new formulations are some major factors behind increased market penetration. On the other hand, subcutaneous drug delivery devices have made tremendous increase in technological aspects which is expected to gain more shares in coming years. As a result, it is expected that new innovative products with higher therapeutic capabilities will enter in market in coming years.

“Subcutaneous Drug Delivery Market & Pipeline Insight” Report Findings:

  • Subcutaneous Drug Delivery Market Overview
  • Devices for Subcutaneous Drug Delivery
  • Subcutaneous Drug Delivery Market Future Prospects
  • Subcutaneous Drug Clinical Pipeline by Company, Indication & Phase
  • Global Subcutaneous Drug Clinical Pipeline: 741 Drugs
  • Global Marketed Subcutaneous Drugs: 228 Drugs
  • Marketed Subcutaneous Drug Clinical Insight

Table of Contents

1. Introduction to Subcutaneous Drug Delivery

2. Mechanism of Subcutaneous Drug Delivery

3. Subcutaneous Drug Delivery Market Overview

  • 3.1. Current Market Scenario
  • 3.2. Subcutaneous Drug Delivery Pipeline Overview

4. Subcutaneous Drug Delivery Market Dynamics

  • 4.1. Favorable market Parameters
  • 4.2. Clinical & Commercialization Challenges

5. Devices for Subcutaneous Drug Delivery

  • 5.1. Syringe Based Subcutaneous Drug Delivery
  • 5.2. Subcutaneous Implants
  • 5.3. Pen Systems for Subcutaneous Drug Delivery
  • 5.4. Auto Injectors
  • 5.5. Pump Based Drug Delivery Systems

6. Subcutaneous Drug Delivery Market Future Prospects

7. Subcutaneous Drug Clinical Pipeline by Company, Indication & Phase

  • 7.1. Unknown
  • 7.2. Research
  • 7.3. Preclinical
  • 7.4. Clinical
  • 7.5. Phase-I
  • 7.6. Phase-I/II
  • 7.7. Phase-II
  • 7.8. Phase-II/III
  • 7.9. Phase-III
  • 7.10. Phase: Preregistration
  • 7.11. Phase: Registered

8. Marketed Subcutaneous Drug Clinical Insight

9. Discontinued & Suspended Subcutaneous Drugs in Clinical Trials

  • 9.1. No Development Reported
  • 9.2. Discontinued
  • 9.3. Preregistration-Submission Withdrawal
  • 9.4. Market Withdrawal
  • 9.5. Suspended

10. Competitive Landscape

  • 10.1. Boehringer Ingelheim
  • 10.2. Eli Lily
  • 10.3. Galaxo
  • 10.4. HMD pharmaceuticals
  • 10.5. Merck
  • 10.6. Novartis
  • 10.7. Novo Nordisk
  • 10.8. Pfizer
  • 10.9. Sanofi
  • 10.10. Teva Pharmaceutical
  • 10.11. Zogenix

List of Figures:

  • Figure 1-1: Functions of Skin Tissue
  • Figure 1-2: Different Functions of Skin Layers
  • Figure 1-3: Benefits of Subcutaneous Drug Delivery Site
  • Figure 1-4: Sites for Subcutaneous Drug Administration
  • Figure 1-5: Limitations of Subcutaneous Drug Delivery Site
  • Figure 2-1: External Factors to Increase Absorbability of Subcutaneous Drugs
  • Figure 2-2: Mechanism of Exogenous Insulin Administration at Subcutaneous Site
  • Figure 3-1: Subcutaneous Drug Delivery Pipeline Phase by (%), 2015
  • Figure 3-2: Subcutaneous Drug Delivery Pipeline Phase by (Numbers), 2015
  • Figure 3-3: No Development Reported Subcutaneous Drug Delivery Pipeline Phase by (%), 2015
  • Figure 3-4: No Development Reported Subcutaneous Drug Delivery Pipeline Phase by (Numbers), 2015
  • Figure 3-5: Discontinued Subcutaneous Drug Delivery Pipeline Phase by (%), 2015
  • Figure 3-6: Discontinued Subcutaneous Drug Delivery Pipeline Phase by (Numbers), 2015
  • Figure 3-7: Suspended Subcutaneous Drug Delivery Pipeline Phase by (%), 2015
  • Figure 3-8: Suspended Subcutaneous Drug Delivery Pipeline Phase by (Numbers), 2015
  • Figure 4-1: Drivers for Intramuscular Drug Delivery Market
  • Figure 4-2: Clinical & Commercialization Challenges
  • Figure 5-1: Classification of Subcutaneous Drug Delivery Devices
  • Figure 5-2: Syringe Based Subcutaneous Drug Delivery
  • Figure 5-3: Implant Based Subcutaneous Drug Delivery
  • Figure 5-4: Description of Pen Systems for Subcutaneous Drug Delivery
  • Figure 5-5: Benefits & Drawbacks Pen Systems for Subcutaneous Drug Delivery
  • Figure 5-6: Auto Injectors for Subcutaneous Drug Delivery
  • Figure 5-7: Different Part of Pump Based Subcutaneous Drug Delivery Device

List of Tables:

  • Table 5-1: Comparative Analysis of Different Subcutaneous Drug Delivery Systems
Back to Top